Literature DB >> 26546222

Naltrexone: Not Just for Opioids Anymore.

Daniel Sudakin1.   

Abstract

Naltrexone is a semi-synthetic opioid with competitive antagonist activity at mu opioid receptors. Its efficacy has been demonstrated in the treatment of alcohol and opioid dependence, but adherence to daily dosing has been recognized as a factor limiting long-term effectiveness. Recently, a long-acting injectable formulation of naltrexone has received FDA-approval for treating alcohol and opioid dependence. This article reviews the pharmacology of naltrexone, the current evidence supporting the use of extended-release naltrexone, and the clinical challenges in the induction of patients to this medication.

Entities:  

Keywords:  Addiction; Alcohol dependence; Naltrexone; Opioid dependence; Toxicology

Mesh：

Substances：

Year:  2016        PMID： 26546222      PMCID： PMC4781804          DOI： 10.1007/s13181-015-0512-x

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN： 1556-9039


  26 in total

Review 1.  Intramuscular extended-release naltrexone: current evidence.

Authors:  David R Gastfriend
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

3.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

4.  Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.

Authors:  Scott E Lukas; Steven B Lowen; Kimberly P Lindsey; Nina Conn; Wendy Tartarini; John Rodolico; Gopi Mallya; Christopher Palmer; David M Penetar
Journal:  Neuroimage       Date:  2013-04-06       Impact factor: 6.556

5.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

6.  Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.

Authors:  Helen M Pettinati; David R Gastfriend; Qunming Dong; Henry R Kranzler; Stephanie S O'Malley
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

7.  Syntheses of novel high affinity ligands for opioid receptors.

Authors:  Mark P Wentland; Rongliang Lou; Qun Lu; Yigong Bu; Christoph Denhardt; Jin Jin; Rakesh Ganorkar; Melissa A VanAlstine; Chengyun Guo; Dana J Cohen; Jean M Bidlack
Journal:  Bioorg Med Chem Lett       Date:  2009-02-25       Impact factor: 2.823

8.  Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects.

Authors:  Elise M Weerts; Yu Kyeong Kim; Gary S Wand; Robert F Dannals; Jae Sung Lee; J James Frost; Mary E McCaul
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

9.  Extended-release naltrexone modulates brain response to drug cues in abstinent heroin-dependent patients.

Authors:  Daniel D Langleben; Kosha Ruparel; Igor Elman; James W Loughead; Elliot L Busch; James Cornish; Kevin G Lynch; Elie S Nuwayser; Anna R Childress; Charles P O'Brien
Journal:  Addict Biol       Date:  2012-07-02       Impact factor: 4.280

10.  The metabolism of naltrexone in man.

Authors:  M E Wall; D R Brine; M Perez-Reyes
Journal:  NIDA Res Monogr       Date:  1981
View more
  12 in total

1.  Low-dose Naltrexone for the treatment of sarcoidosis.

Authors:  Leonard B Weinstock; Trisha L Myers; Anup Shetty
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

Review 2.  Orphan neuropeptides and receptors: Novel therapeutic targets.

Authors:  Lloyd D Fricker; Lakshmi A Devi
Journal:  Pharmacol Ther       Date:  2017-11-22       Impact factor: 12.310

3.  Translational and Molecular Cytoarchitectural Genetic Guided Therapy to Induce Dopamine Homeostatic Neuro-signaling in Reward Deficiency and Associated Drug and Behavioral Addiction Seeking: A 60 Year Sojourn the Future is Now.

Authors:  Kenneth Blum; Rajendra D Badgaiyan
Journal:  EC Psychol Psychiatr       Date:  2021-07-29

4.  Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain.

Authors:  Gabriela Dieckmann; M Cuneyt Ozmen; Stephanie M Cox; Ryan C Engert; Pedram Hamrah
Journal:  Ocul Surf       Date:  2021-01-12       Impact factor: 6.268

5.  From binge eating to binge drinking: A new and robust paradigm for assessing binge ethanol self-administration in male rats.

Authors:  Leandro Ruiz-Leyva; Ana Vázquez-Ágredos; Ana M Jiménez-García; Olga López-Guarnido; Antonio Pla; Ricardo Marcos Pautassi; Ignacio Morón Henche; Cruz Miguel Cendán
Journal:  Addict Biol       Date:  2022-03       Impact factor: 4.093

Review 6.  The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review.

Authors:  Raewyn Rees; Ali Seyfoddin
Journal:  J Pharm Policy Pract       Date:  2017-07-11

Review 7.  Nanoparticle delivery systems for substance use disorder.

Authors:  Vishal Kasina; Robert J Mownn; Raman Bahal; Gregory C Sartor
Journal:  Neuropsychopharmacology       Date:  2022-03-28       Impact factor: 8.294

8.  Design and Characterization of Spray-Dried Chitosan-Naltrexone Microspheres for Microneedle-Assisted Transdermal Delivery.

Authors:  Abayomi T Ogunjimi; Jennifer Fiegel; Nicole K Brogden
Journal:  Pharmaceutics       Date:  2020-05-29       Impact factor: 6.321

9.  Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder.

Authors:  Jarrod Ehrie; Emily E Hartwell; Paige E Morris; Tami L Mark; Henry R Kranzler
Journal:  Front Psychiatry       Date:  2020-02-14       Impact factor: 4.157

Review 10.  Monitoring and Improving Naltrexone Adherence in Patients with Substance Use Disorder.

Authors:  Virginia Perez-Macia; Mireia Martinez-Cortes; Jesus Mesones; Manuel Segura-Trepichio; Lorena Garcia-Fernandez
Journal:  Patient Prefer Adherence       Date:  2021-05-18       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.